Drug Topics
NOVEMBER 3, 2024
In case you missed it, this week we had stories about PBMs' threat to independent pharmacies, the risks and benefits of AI in pharmacy, pharmacists' role in hormonal prescribing, and more.
Pharmacy Times
NOVEMBER 3, 2024
Two clinical trials with MRD monitoring may be practice changing: TRACERx and AEGEAN.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 3, 2024
ESSENCE trial of Novo Nordisk's GLP-1 drug semaglutide shows efficacy in MASH, setting up filings in the US and Europe next year
BioPharm
NOVEMBER 3, 2024
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
NOVEMBER 3, 2024
Under a final rule issued by the Centers for Medicare and Medicaid Services, outpatient hospital facilities and ambulatory surgical centers will get a 2.9% Medicare pay increase next year, up from | Under a final rule issued by CMS, outpatient hospital facilities and ambulatory surgical centers will get a 2.9% Medicare pay increase next year, up from the 2.6% boost in reimbursement that was floated in the draft rule.
Med Ed 101
NOVEMBER 3, 2024
There are two agents that are frequently used in alcohol use disorder. Acamprosate and naltrexone have distinct advantages and disadvantages in the treatment of alcohol use disorder. In this article, we will compare the clinical benefits and risks of acamprosate vs naltrexone. What do the guidelines say? Both naltrexone and acamprosate are considered first-line treatments […] The post Acamprosate vs Naltrexone – Clinical Comparison appeared first on Med Ed 101.
Expert insights. Personalized for you.
190 
Let's personalize your content